Complete Among Known Outcome · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete Among Known Outcome compared with chemotherapy Alone (very low certainty).
1 finding from 1 review
RR 4.25 [0.7, 25.91]
30 participants
Very low
Complete/Partial Among Known Outcome · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes complete/Partial Among Known Outcome compared with chemotherapy Alone (very low certainty).
1 finding from 1 review
RR 1.01 [0.81, 1.27]
30 participants
Very low
All‐cause mortality · Kaposi sarcoma in children with HIV‐1 infection
It is very uncertain whether chemotherapy + ART changes mortality compared with chemotherapy Alone (very low certainty).
1 finding from 1 review
RR 0.46 [0.29, 0.73]
98 participants
Very low
Intervention not reported
Objective response rate2 · Patients with advanced non‐small cell lung cancer
The intervention may leads to higher objective response rate2 (low certainty).
1 finding from 1 review
Parasitological failure at 1 month · People with S. mansoni infection
It is very uncertain whether artesunate (12 mg/kg) plus praziquantel (40 mg/kg) changes parasitological failure at 1 month compared with praziquantel (40 mg/kg) alone (very low certainty).
1 finding from 1 review
Requirement for anticholinergics number of participants requiring medication for extrapyramidal side effects · patients with an acute manic or mixed episode
Aripiprazole leads to higher requirement for anticholinergics number of participants requiring… compared with placebo (high certainty).
1 finding from 1 review
RR 3.28 [1.82, 5.91]
730 participants
High
Retention in treatment · patients with treatment of opioid dependence
Any Psychosocial intervention plus pharm showed no clear difference in retention in treatment Objective compared with pharm standard (high certainty).
1 finding from 1 review
Opioid abstinence objective · patients with treatment of opioid dependence
Any Psychosocial intervention plus pharm showed no clear difference in opioid abstinence objective compared with pharm standard (high certainty).
1 finding from 1 review
Compliance · patients with treatment of opioid dependence
1 finding from 1 review
Time to recurrence · transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer
NBI + WLC TURBT may leads to lower time to disease recurrence compared with WLC TURBT (low certainty).
1 finding from 1 review
Time to progression · transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clavien‐Dindo grade ≥ 3 complications · transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer
NBI + WLC TURBT showed no clear difference in major adverse event (Clavien‐Dindo grade III, IV, and V) compared with WLC TURBT (low certainty).
1 finding from 1 review
Time to death from bladder cancer · transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clavien‐Dindo grade ≤ 2 complications8 · transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer
NBI + WLC TURBT showed no clear difference in minor adverse event (Clavien‐Dindo grade I and II) compared with WLC TURBT (low certainty).
1 finding from 1 review
Overall survival (Death) · patients with advanced and/or metastatic colorectal cancer
IRI with fluoropyrimidines showed no clear difference in overall survival (Death) compared with single agent IRI (low certainty).
1 finding from 1 review
Progression‐free survival (PSF) · patients with advanced and/or metastatic colorectal cancer
IRI with fluoropyrimidines probably leads to lower progression‐free survival (Disease progression) compared with single agent IRI (moderate certainty).
1 finding from 1 review
Grade 3/4 diarrhea · patients with advanced and/or metastatic colorectal cancer
IRI with fluoropyrimidines probably leads to lower grade 3/4 diarrhea compared with single agent IRI (moderate certainty).
1 finding from 1 review
Grade 3/4 nausea · patients with advanced and/or metastatic colorectal cancer
IRI with fluoropyrimidines showed no clear difference in grade 3/4 nausea compared with single agent IRI (low certainty).
1 finding from 1 review
Intervention not reported
Lymph node mets analysis ‐ N+ OS · patients with resectable gastric cancer
The intervention probably leads to lower lymph node mets analysis ‐ N+ OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Chemobased OS ‐ 5‐FU based chemotherapy OS · patients with resectable gastric cancer
The intervention probably leads to lower chemobased OS ‐ 5‐FU based chemotherapy OS (moderate certainty).
1 finding from 1 review